:: N E W S ::

Mercator MedSystems Raises Additional $6.5 Million

Mercator MedSystems Announces European Market Clearance for its Groundbreaking Adventitial Drug Delivery Catheters

One-Year Follow-Up Results From Athersys' Phase I Study of MultiStem in Heart Attack Patients Presented at International Stem Cell Symposium

Mercator MedSystems Appoints Neil Desai, PhD, to Board of Directors

Mercator MedSystems Receives Grant from Department of Treasury - Third Federal Grant this Year

Promising New Therapy for Drug-Resistant Hypertension Presented at Interventional Cardiology Meeting in Washington, D.C.

The second-generation Bullfrog^® and Cricket™ Micro-Infusion Catheters have received FDA 510(k) marketing clearance

Mercator MedSystems, Inc. is a medical technology company focused on the treatment of hypertension utilizing its catheter-guided, microfluid injection systems for site-specific, non-systemic delivery of therapeutic agents directly across any blood vessel. The Company’s technology also enables the commercialization of novel therapeutics for other vascular diseases, oncology, and regenerative medicine. The Company's Cricket™ and Bullfrog^® Micro-Infusion Catheters are the first vascular-access systems able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery ::